Sotera Health Co (SHC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sotera Health Co stock (SHC) is currently trading at $13.70. Sotera Health Co PE ratio is 51.24. Sotera Health Co PS ratio (Price-to-Sales) is 3.38. Analyst consensus price target for SHC is $20.75. WallStSmart rates SHC as Hold.
- SHC PE ratio analysis and historical PE chart
- SHC PS ratio (Price-to-Sales) history and trend
- SHC intrinsic value — DCF, Graham Number, EPV models
- SHC stock price prediction 2025 2026 2027 2028 2029 2030
- SHC fair value vs current price
- SHC insider transactions and insider buying
- Is SHC undervalued or overvalued?
- Sotera Health Co financial analysis — revenue, earnings, cash flow
- SHC Piotroski F-Score and Altman Z-Score
- SHC analyst price target and Smart Rating
Sotera Health Co
📊 No data available
Try selecting a different time range
SHC Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Sotera Health Co (SHC)
SHC trades 37% above its Graham fair value of $12.64, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Sotera Health Co (SHC) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, eps growth, institutional own.. Concerns around price/book and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Sotera Health Co (SHC) Key Strengths (5)
Keeps $36 of every $100 in revenue after operating costs
Earnings per share surging 175.40% year-over-year
85.56% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Solid profitability: $15 profit per $100 equity
Supporting Valuation Data
Sotera Health Co (SHC) Areas to Watch (5)
Very expensive at 6.3x book value
Revenue growing slowly at 4.60% annually
Thin profit margins with limited profitability
Growth is fairly priced, not cheap, not expensive
Revenue is fairly priced at 3.38x sales
Supporting Valuation Data
Sotera Health Co (SHC) Detailed Analysis Report
Overall Assessment
This company scores 62/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 8.8/10) while 5 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, EPS Growth, Institutional Own.. Profitability is solid with Return on Equity at 15.40%, Operating Margin at 35.70%. Growth metrics are encouraging with EPS Growth at 175.40%.
The Bear Case
The primary concerns are Price/Book, Revenue Growth, Profit Margin. Some valuation metrics including PEG Ratio (1.68), Price/Sales (3.38), Price/Book (6.34) suggest expensive pricing. Growth concerns include Revenue Growth at 4.60%, which may limit upside. Profitability pressure is visible in Profit Margin at 6.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 15.40% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 4.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Operating Margin, EPS Growth) and negatives (Price/Book, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SHC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SHC's Price-to-Sales ratio of 3.38x sits near its historical average of 3.51x (29th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 15% below its historical high of 3.97x set in Mar 2026, and 3% above its historical low of 3.28x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~4.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Sotera Health Co (SHC) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Sotera Health Co operates as a stable business with moderate growth and solid fundamentals. Revenue reached 1.2B with 5% growth year-over-year. Profit margins are thin at 6.7%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Generating 52M in free cash flow and 103M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of 4.14 is elevated. High leverage amplifies both gains and losses and increases financial risk.
What to Watch Next
Margin expansion: can Sotera Health Co push profit margins above 15% as the business scales?
Valuation compression risk at a P/E of 51.2x. Any growth miss could trigger a sharp correction.
Volatility is elevated with a beta of 1.88, so expect amplified moves relative to the broader market.
Debt management: total debt of 2.3B is significantly higher than cash (301M). Monitor refinancing risk.
Bottom Line
Sotera Health Co offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(28 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 4:27:26 PM
About Sotera Health Co(SHC)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.